Biosimilars in Finland

The following biomisimilars were available in the Finnish markets in the summer 2016:

Name Active substance Reference product Marketing authorisation date
Abasaglar insulin glargine Lantus 9 September 2014
Bemfola Follitropin alpha Gonal-F 27 March 2014
Binocrit epoetin alfa Eprex/Erypo 28 August 2007
Inflectra infliximab Remicade 10 September 2013
Nivestim filgrastim Neupogen 8 June 2010
Omnitrope somatropin Genotropin 12 April 2006
Ratiograstim filgrastim Neupogen 15 September 2008
Remsima infliximab Remicade 10 September 2013
Retacrit epoetin zeta Eprex/Erypo 18 December 2007
Zarzio filgrastim Neupogen 6 February 2009